Osteoboost Secures $8M to Expand Access to its FDA-Cleared Prescription Wearable for Bone Health

Osteoboost Health, Inc., today announced it has closed an $8 million financing round to scale manufacturing, expand clinical research, and broaden the commercial reach of the company’s FDA-cleared medical device for low bone density. The round was led by Ambit Health Ventures, with participation from new investors including Emmeline Ventures and Disrupt Health Impact Fund, as well as existing investors Esplanade Ventures and Portfolia.

Nearly 10 million Americans have osteoporosis, and another 44 million live with low bone density. However, few options exist for women to proactively get ahead of age-related bone loss, especially during menopause when bone density declines rapidly. Osteoboost, a class II prescription medical device, is the first and only FDA-cleared, non-drug treatment clinically proven to treat low bone density in postmenopausal women with osteopenia, the precursor to osteoporosis.

“The cost of osteoporosis to society is enormous, but this is not a condition that begins at diagnosis. It develops silently over many years,” said Laura Yecies, chief executive officer of Osteoboost Health. “That’s why earlier intervention and prevention are so critical, especially for women entering menopause—when bone loss is known to accelerate. This funding advances Osteoboost’s vision of building a complete bone health solution and changing the trajectory of bone health for millions.”

Worn low around the hips and over the sacrum, Osteoboost delivers targeted, low-magnitude, precisely calibrated vibration therapy directly to the lumbar spine and hips, regions most vulnerable to fracture. The treatment was inspired by NASA-funded research and was proven in a gold-standard, double-blinded clinical trial at the University of Nebraska Medical Center to slow bone density loss by 85% in the spine and 55% in the hips, respectively, for patients who used the device 3 times per week or more for 30- minute sessions during a 12-month period.

“At Emmeline, we invest in companies tackling the biggest unmet needs in women’s health,” said Azin Radsan van Alebeek, co-founder & general partner at Emmeline Ventures. “Half of women over 50 will experience a fracture due to bone loss, yet osteoporosis remains dramatically underdiagnosed and undertreated. Laura and the Osteoboost team are bringing much-needed innovation to bone health, and we’re excited to support their mission.”

Women’s health remains underfunded relative to the scale of need. A January 2026 World Economic Forum report found the sector receives just 6% of private healthcare capital, with most funding concentrated in reproductive health, maternal care, and women’s oncology. While venture dollars have favored software and AI over regulated medical devices, populations are aging quickly. The World Health Organization projects that by 2030, one in six people worldwide will be aged 60 or older, increasing demand for solutions that support strength, mobility, and independence for seniors.

“For years, when a patient with osteopenia asked what they could do beyond calcium, vitamin D, and exercise, we didn’t have much to offer,” said David B. Karpf, an endocrinologist and attending physician in the Osteoporosis & Metabolic Bone Disease Clinic at Stanford University School of Medicine. “Many of the women I treat are younger peri- and post-menopausal women who have osteopenia, and want to do everything they can to prevent developing osteoporosis, in order to stay strong enough to travel, exercise, and lift their grandchildren. But there are no approved drug therapies for osteopenia. This gap between diagnosis and drug therapy has been frustrating. The availability of the FDA-approved Osteoboost device provides a clinically supported, non-drug option that allows us to intervene earlier.”

As part of a vision to offer a complete bone health solution, the company also offers Wellen by Osteoboost, an online asynchronous video-based training platform developed by physical therapists for people with osteoporosis. In a study of 680 participants, Wellen users improved lower-body strength by 22.8% after one 18-session series, and nearly 80% of those who began at elevated fall risk improved to average or above-average levels.

“Osteoboost appealed to me on so many levels,” said Esther Dyson, Osteoboost user and early investor. “As someone who has trained to go into space but has not actually gone - yet! - I knew about the original NASA research. I also have low bone density and a cracked (but not broken) femur from a fall, so I’m excited to see an alternative to the standard pharmaceutical approach.”

Osteoboost was designated a Breakthrough Device by the U.S. Food and Drug Administration in 2024 and cleared through the De Novo pathway.

Devices began shipping last May and have been prescribed by more than 2,500 unique physicians, including clinical professionals at more than 30 leading academic medical centers. The device was named to TIME’s 2025 list of Best Inventions.

To learn more about Osteoboost, visit www.osteoboost.com

About Osteoboost Health, Inc.

Osteoboost Health is a Redwood City-based company that applies science and medical expertise to create better health outcomes for women and men at risk of osteoporosis and bone fractures. The company’s first FDA-approved device, Osteoboost, is poised to become the new standard of care in treating postmenopausal osteopenia. Osteoboost Health is backed by leading investors, including Esplanade Ventures, Terumo Medical Corporation, Ambit Health Ventures, Good Growth Capital, Portfolia, Astia Angels, AARP, and Golden Seeds. For more information about Osteoboost, including the full Indications for Use, please visit www.osteoboost.com.

Contact Information

VSC for Osteoboost

PR for Osteoboost

VSC

osteoboost@vsc.co